Advertisement
Organisation › Details
Kurma Biofund III
In December 2018 Kurma Partners has completed the first closing of its third Biofund, Kurma Biofund III, with a target for the final closing of €150m. Kurma Biofund III is backed by cornerstone investors including Servier, Bpifrance and Idinvest. Kurma Biofund III will invest in private companies, addressing high unmet medical and patient needs. The previous Biofund, Kurma Biofund II invested in twelve companies, among which four: Step Pharma, Dynacure, ImCheck and Pharvaris, were (co)-created by Kurma under this model. With this new fund, the team will build a portfolio of approximately twelve to fifteen companies, of which four to five will be new companies founded by Kurma Partners. As for its other funds, Kurma associated a mix of strategic investor and long-term LPs to create the conditions for this first close. Servier, Bpifrance and Idinvest are cornerstone investors and will have a seat at the fund Advisory Committee. Other institutional investors and family offices are also part of this first closing. *
Start | 2018-12-14 fund closing 1st | |
Group | Eurazeo (Group) | |
Predecessor | Kurma Biofund II (The Orphan Initiative) | |
Industry | venture capital | |
Industry 2 | LIFE SCIENCES | |
Person | Laugel, Thierry (Kurma Life Sciences Partners 201103 Managing Partner at Kurma BioFund before AGF Private Equity) | |
Person 2 | Droller, Rémi (Kurma 201305 Managing Partner at Kurma Life Sciences Partners) | |
Region | Paris | |
Country | France | |
City | n. a. Paris | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
Currency | EUR | |
Annual sales | 160,000,000 (fund size, at closing (2020) 2020-04-29) | |
* Document for »About Section«: Kurma Partners. (12/14/18). "Press Release: Kurma Partners Announces the First Closing of Kurma Biofund III". Paris. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Eurazeo (Group)
- [1] Kurma Partners. (3/7/22). "Press Release: Kurma Partners Targets €250 Million for its First Growth Opportunities Fund". Paris....
- [2] PathoQuest S.A.S.. (11/9/21). "Press Release: PathoQuest Closes up to €15 Million Series B Financing Round Led by Growth Investor SHS Capital". Paris & Tübingen....
- [3] Arkhn S.A.S.. (5/17/21). "Press Release: Arkhn Raises €4 Million to Lead Healthcare Institutions Towards Sovereign and Efficient Data Management". Paris....
- [4] Kaia Health Software GmbH. (4/28/21). "Press Release: Kaia Health Raises $75 Million Series C to Optimize MSK and COPD Care in the U.S. and Europe". New York, NY....
- [5] Kurma Partners. (4/13/21). "Press Release: Jean-François Rivassou Joins Kurma Partners as Partner". Paris....
- [6] Synendos Therapeutics AG. (11/12/20). "Press Release: Synendos Therapeutics Raises CHF 20 Million in Series A Financing". Basel....
- [7] Kurma Partners. (11/9/20). "Press Release: Kurma Partners Strengthens Its Teams and Promotes Its Talents". Paris....
- [8] Corlieve Therapeutics S.A.S.. (11/2/20). "Press Release: Corlieve Therapeutics SAS Closes Seed Financing to Develop Therapies for Severe Neurological Conditions". Paris....
- [9] Kurma Partners. (9/29/20). "Press Release: Kurma Partners Announces the First Closing of Kurma Diagnostics 2 (KDx2) Fund at €50 Million". Paris....
- [10] Lifebit Biotech Ltd.. (4/30/20). "Press Release: Lifebit Closes $7.5M Million Series A Round to Accelerate Global Market Expansion". London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top